{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:15:14Z","timestamp":1788520514950,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006022","name":"Minist\u00e8re des Affaires Sociales, de la Sant\u00e9 et des Droits des Femmes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The randomized controlled trial Inter-B-NHL ritux 2010 showed overall survival (OS) benefit and event-free survival (EFS) benefit with the addition of rituximab to standard Lymphomes Malins B (LMB) chemotherapy in children and adolescents with high-risk, mature B cell non-Hodgkin\u2019s lymphoma. Our aim was to assess the cost-effectiveness of rituximab-chemotherapy versus chemotherapy alone in the French setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used a decision-analytic semi-Markov model with four health states and 1-month cycles. Resource use was prospectively collected in the Inter-B-NHL ritux 2010 trial (NCT01516580). Transition probabilities were assessed from patient-level data from the trial (<jats:italic>n<\/jats:italic>\u2009=\u2009328). In the base case analysis, direct medical costs from the French National Insurance Scheme and life-years (LYs) were computed in both arms over a 3-year time horizon. Incremental net monetary benefit and cost-effectiveness acceptability curve were computed through a probabilistic sensitivity analysis. Deterministic sensitivity analysis and several sensitivity analyses on key assumptions were also conducted, including one exploratory analysis with quality-adjusted life years as the health outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>OS and EFS benefits shown in the Inter-B-NHL ritux 2010 trial translated into the model by rituximab-chemotherapy being the most effective and also the least expensive strategy over the chemotherapy strategy. The mean difference in LYs between arms was 0.13 [95% CI 0.02; 0.25], and the mean cost difference \u20ac \u2212 3 710 [95% CI \u20ac \u2212 17,877; \u20ac 10,525] in favor of rituximab-chemotherapy group. For a \u20ac 50,000 per LY willingness-to-pay threshold, the probability of the rituximab-chemotherapy strategy being cost-effective was 91.1%. All sensitivity analyses confirmed these findings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Adding rituximab to LMB chemotherapy in children and adolescents with high-risk mature B-cell non-Hodgkin's lymphoma is highly cost-effective in France.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov identifier: NCT01516580.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-023-01581-y","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T12:01:56Z","timestamp":1681473716000},"page":"307-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"25","clinical-trial-number":[{"clinical-trial-number":"nct01516580","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"B\u00e9ranger","family":"Lueza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Aup\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Rigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael F.","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Uyttebroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2671-9972","authenticated-orcid":false,"given":"G. A.","family":"Amos Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"Zs\u00edros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Cs\u00f3ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Simonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Patte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Minard-Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-0072","authenticated-orcid":false,"given":"Julia","family":"Bonastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"1581_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B cell lymphoma. N. Engl. J. Med. 346, 235\u2013242 (2002)","journal-title":"N. Engl. J. Med."},{"key":"1581_CR2","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier, P., Van Hoof, A., Sebban, C., et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J. Clin. Oncol. 23, 4117\u20134126 (2005)","journal-title":"J. Clin. Oncol."},{"key":"1581_CR3","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann, T.M., Weller, E.A., Morrison, V.A., et al.: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B cell lymphoma. J. Clin. Oncol. 24, 3121\u20133127 (2006)","journal-title":"J. Clin. Oncol."},{"key":"1581_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh, M., Tr\u00fcmper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., L\u00f3pez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E., Loeffler, M., MabThera International Trial Group: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. (2006). https:\/\/doi.org\/10.1016\/S1470-2045(06)70664-7","journal-title":"Lancet Oncol."},{"issue":"10036","key":"1581_CR5","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","volume":"387","author":"V Ribrag","year":"2016","unstructured":"Ribrag, V., Koscielny, S., Bosq, J., Leguay, T., Casasnovas, O., Fornecker, L.M., Recher, C., Ghesquieres, H., Morschhauser, F., Girault, S., Le Gouill, S., Ojeda-Uribe, M., Mariette, C., Cornillon, J., Cartron, G., Verge, V., Chassagne-Cl\u00e9ment, C., Dombret, H., Coiffier, B., Lamy, T., Tilly, H., Salles, G.: Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 387(10036), 2402\u20132411 (2016). https:\/\/doi.org\/10.1016\/S0140-6736(15)01317-3","journal-title":"Lancet"},{"issue":"23","key":"1581_CR6","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","volume":"382","author":"V Minard-Colin","year":"2020","unstructured":"Minard-Colin, V., Aup\u00e9rin, A., Pillon, M., et al.: Rituximab for high-risk, mature B cell non-Hodgkin\u2019s lymphoma in children. N. Engl. J. Med. 382(23), 2207\u20132219 (2020). https:\/\/doi.org\/10.1056\/NEJMoa1915315","journal-title":"N. Engl. J. Med."},{"key":"1581_CR7","unstructured":"European medicine agency. Mabthera Product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf"},{"key":"1581_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ahj.2004.11.001","volume":"149","author":"SD Reed","year":"2005","unstructured":"Reed, S.D., Anstrom, K.J., Bakhai, A., et al.: Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am. Heart J. 149, 434\u2013443 (2005)","journal-title":"Am. Heart J."},{"key":"1581_CR9","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Choices in methods for economic evaluation\u2014HAS. April 2020 https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-11\/methodological_guidance_2020_-choices_in_methods_for_economic_evaluation.pdf Accessed 21 Jan 2023"},{"key":"1581_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"Siebert","year":"2012","unstructured":"Siebert, et al.: State-Transition modeling: a report of the ISPOR-SMDM. modeling good research practices task force-3. Value Health. 15, 812\u2013820 (2012)","journal-title":"Value Health."},{"key":"1581_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","volume":"18","author":"S Ramsey","year":"2015","unstructured":"Ramsey, S., Willke, R., Glick, H., et al.: Cost-effectiveness analysis alongside clinical trials II\u2014an ISPOR good research practives task force report. Value Health. 18, 161\u2013172 (2015)","journal-title":"Value Health."},{"key":"1581_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1049","volume":"346","author":"D Husereau","year":"2013","unstructured":"Husereau, D., Drummond, M., Petrou, S., et al.: Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ 346, f1049 (2013)","journal-title":"BMJ"},{"issue":"11","key":"1581_CR13","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","volume":"97","author":"C Patte","year":"2001","unstructured":"Patte, C., Auperin, A., Michon, J., et al.: The Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97(11), 3370\u20133379 (2001)","journal-title":"Blood"},{"issue":"6","key":"1581_CR14","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3324\/haematol.2014.121434","volume":"100","author":"A Jourdain","year":"2015","unstructured":"Jourdain, A., Auperin, A., Minard-Colin, V., et al.: Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective \u201cLymphomes Malins B\u201d protocols. A \u00ab\u202fSoci\u00e9t\u00e9 Fran\u00e7aise des Cancers de l\u2019Enfant\u202f\u00bb study. Haematologica 100(6), 810\u2013817 (2015)","journal-title":"Haematologica"},{"key":"1581_CR15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40273-021-01034-5","volume":"39","author":"T Srivastava","year":"2021","unstructured":"Srivastava, T., Latimer, N.R., Tappenden, P.: Estimation of transition probabilities for state-transition models: a review of NICE appraisals. Pharmacoeconomics 39, 869\u2013878 (2021)","journal-title":"Pharmacoeconomics"},{"key":"1581_CR16","doi-asserted-by":"publisher","DOI":"10.3310\/hta8370","author":"C Knight","year":"2004","unstructured":"Knight, C., Hind, D., Brewer, N., Abbott, V.: Rituximab (MabThera\u00ae) for aggressive non-Hodgkin\u2019s lymphoma: systematic review and economic evaluation. Health Technol. Assess. (2004). https:\/\/doi.org\/10.3310\/hta8370","journal-title":"Health Technol. Assess."},{"key":"1581_CR17","volume-title":"Economic evaluation in clinical trials","author":"HA Glick","year":"2007","unstructured":"Glick, H.A., Doshi, J.A., Sonnad, S.S., et al.: Economic evaluation in clinical trials. Oxford University Press, Oxford (2007)"},{"key":"1581_CR18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick, E., Claxton, K., Sculpher, M.: Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 10, 779\u2013787 (2001)","journal-title":"Health Econ."},{"key":"1581_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00044011-200828010-00007","volume":"28","author":"F Ferrara","year":"2008","unstructured":"Ferrara, F., Ravasio, R.: Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B cell lymphoma. Clin. Drug Investig. 28, 55\u201365 (2008)","journal-title":"Clin. Drug Investig."},{"issue":"7","key":"1581_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2165\/11591160-000000000-00000","volume":"30","author":"PW Auweiler","year":"2012","unstructured":"Auweiler, P.W., M\u00fcller, D., Stock, S., Gerber, A.: Cost effectiveness of rituximab for non-Hodgkin\u2019s lymphoma: a systematic review. Pharmacoeconomics 30(7), 537\u2013549 (2012). https:\/\/doi.org\/10.2165\/11591160-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1581_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF03320633","volume":"6","author":"P Berto","year":"2004","unstructured":"Berto, P., Morsanutto, A., Lopatriello, S., et al.: Analisi costoefficacia di Rituximab +CHOP versus CHOP in soggetti affetti da linfoma non-Hodgkin aggressivo. Pharmacoeconomics Italian Research Articles. 6(3), 151\u2013160 (2004)","journal-title":"Pharmacoeconomics Italian Research Articles."},{"issue":"1","key":"1581_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF03320566","volume":"9","author":"P Berto","year":"2007","unstructured":"Berto, P., Lopatriello, S., Arcaini, L., et al.: Costo-efficacia dirituximab nella terapia di mantenimento in soggetti affettida linfoma non-Hodgkin follicolare refrattario. Pharmacoeconomics Italian Research Articles. 9(1), 9\u201319 (2007)","journal-title":"Pharmacoeconomics Italian Research Articles."},{"issue":"4","key":"1581_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1524-4733.2005.00037.x","volume":"8","author":"JH Best","year":"2005","unstructured":"Best, J.H., Hornberger, J., Proctor, S.J., et al.: Cost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B cell lymphoma. Value Health. 8(4), 462\u2013470 (2005)","journal-title":"Value Health."},{"issue":"1","key":"1581_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","volume":"28","author":"E Deconinck","year":"2010","unstructured":"Deconinck, E., Miadi-Fargier, H., Le Pen, C., et al.: Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics 28(1), 35\u201346 (2010)","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1581_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1600-0609.2004.00368.x","volume":"74","author":"MT Groot","year":"2005","unstructured":"Groot, M.T., Lugtenburg, P.J., Hornberger, J., et al.: Cost-effectiveness of rituximab (MabThera) in diffuse large B cell lymphoma in the Netherlands. Eur. J. Haematol. 74(3), 194\u2013202 (2005)","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"1581_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1524-4733.2009.00676.x","volume":"13","author":"JA Ray","year":"2010","unstructured":"Ray, J.A., Carr, E., Lewis, G., et al.: An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin\u2019s lymphoma in the UK. Value Health. 13(4), 346\u2013355 (2010)","journal-title":"Value Health."},{"issue":"1","key":"1581_CR27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1130-6343(08)72806-X","volume":"32","author":"Grupo de Farmacoeconomia del Linfoma Folicular","year":"2008","unstructured":"Grupo de Farmacoeconomia del Linfoma Folicular: Rituximab cost analysis for maintenance treatment of patients with follicular lymphoma [in Spanish]. Farm. Hosp. 32(1), 25\u201334 (2008)","journal-title":"Farm. Hosp."},{"issue":"3","key":"1581_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3816\/CLM.2008.n.020","volume":"8","author":"JW Hayslip","year":"2008","unstructured":"Hayslip, J.W., Simpson, K.N.: Cost-effectiveness of extended adjuvant rituximab for US patients aged 65\u201370 years with follicular lymphoma in second remission. Clin. Lymphoma Myeloma. 8(3), 166\u2013170 (2008)","journal-title":"Clin. Lymphoma Myeloma."},{"issue":"8","key":"1581_CR29","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/cncr.20956","volume":"103","author":"JC Hornberger","year":"2005","unstructured":"Hornberger, J.C., Best, J.H.: Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B cell lymphoma. Cancer 103(8), 1644\u20131651 (2005)","journal-title":"Cancer"},{"issue":"2","key":"1581_CR30","first-page":"227","volume":"49","author":"J Hornberger","year":"2008","unstructured":"Hornberger, J., Reyes, C., Lubeck, D., et al.: Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. LeukemiaLymphoma. 49(2), 227\u2013236 (2008)","journal-title":"LeukemiaLymphoma."},{"issue":"6","key":"1581_CR31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/02841860802120028","volume":"47","author":"F Kasteng","year":"2008","unstructured":"Kasteng, F., Erlanson, M., Hagberg, H., et al.: Cost-effectiveness of maintenance rituximab treatment after second-line therapy in patients with follicular lymphoma in Sweden. Acta Oncol. 47(6), 1029\u20131036 (2008)","journal-title":"Acta Oncol."},{"key":"1581_CR32","volume-title":"Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin\u2019s lymphoma: review of technology appraisal 37","author":"National Institute for Health and Clinical Excellence","year":"2008","unstructured":"National Institute for Health and Clinical Excellence: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin\u2019s lymphoma: review of technology appraisal 37. NICE, London (2008)"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-023-01581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-023-01581-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-023-01581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T10:04:56Z","timestamp":1707559496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-023-01581-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1581"],"URL":"https:\/\/doi.org\/10.1007\/s10198-023-01581-y","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"assertion":[{"value":"15 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anne Aup\u00e9rin: Research funding (recipient: institution): F Hoffmann- La Roche- Genentec. G.A. Amos Burke: Consulting or advisory role with compensation for the institution: F Hoffmann- La Roche, Janssen, Novartis, Takeda. Catherine Patte: Research funding (recipient: institution): F Hoffmann- La Roche. V\u00e9ronique Minard-Colin: Consulting or advisory role with compensation for the institution: Roche, BMS, Novartis; Research funding (recipient: institution): F Hoffmann- La Roche, BMS. Julia Bonastre: Consulting or advisory role with individual compensation: Astellas, BMS, MSD; Travel expenses: BMS. The other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}